Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
Adult
Antibodies, Monoclonal, Humanized
/ administration & dosage
Dermatologic Agents
/ administration & dosage
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Placebos
Psoriasis
/ drug therapy
Randomized Controlled Trials as Topic
Severity of Illness Index
Treatment Outcome
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
02
07
2018
accepted:
14
11
2018
pubmed:
7
3
2019
medline:
3
1
2020
entrez:
7
3
2019
Statut:
ppublish
Résumé
Efficacy of tildrakizumab for plaque psoriasis was demonstrated in randomized, placebo-controlled trials. To consolidate tildrakizumab efficacy results by pooling data. Data (N = 2081) from tildrakizumab 100 mg, tildrakizumab 200 mg and placebo groups in three trials were pooled. Proportions of Psoriasis Area and Severity Index (PASI) 75 responders at week 12 were better with tildrakizumab 100 mg (62.3%) and tildrakizumab 200 mg (64.8%) vs. placebo (5.6%; P < 0.0001) and for PASI 90, PASI 100 and Physician's Global Assessment (PGA) 'clear' or 'minimal' vs. placebo (P < 0.0001). Responses increased from weeks 12 to 28. Week 12 PASI and PGA responses to tildrakizumab vs. placebo were numerically greater in patients with lower vs. higher bodyweight and were better with tildrakizumab 200 mg than tildrakizumab 100 mg for patients with higher bodyweight. Week 12 PASI 75 responses vs. placebo with tildrakizumab 100 mg were similar between patients with (55.0%) or without (56.7%) prior biologics. PASI 90, PASI 100 and PGA responses were generally higher in patients without prior biologics. Week 8 PASI 50 response predicted PASI 90 response. Pooled data confirmed the efficacy of tildrakizumab for moderate-to-severe plaque psoriasis.
Sections du résumé
BACKGROUND
BACKGROUND
Efficacy of tildrakizumab for plaque psoriasis was demonstrated in randomized, placebo-controlled trials.
OBJECTIVE
OBJECTIVE
To consolidate tildrakizumab efficacy results by pooling data.
METHODS
METHODS
Data (N = 2081) from tildrakizumab 100 mg, tildrakizumab 200 mg and placebo groups in three trials were pooled.
RESULTS
RESULTS
Proportions of Psoriasis Area and Severity Index (PASI) 75 responders at week 12 were better with tildrakizumab 100 mg (62.3%) and tildrakizumab 200 mg (64.8%) vs. placebo (5.6%; P < 0.0001) and for PASI 90, PASI 100 and Physician's Global Assessment (PGA) 'clear' or 'minimal' vs. placebo (P < 0.0001). Responses increased from weeks 12 to 28. Week 12 PASI and PGA responses to tildrakizumab vs. placebo were numerically greater in patients with lower vs. higher bodyweight and were better with tildrakizumab 200 mg than tildrakizumab 100 mg for patients with higher bodyweight. Week 12 PASI 75 responses vs. placebo with tildrakizumab 100 mg were similar between patients with (55.0%) or without (56.7%) prior biologics. PASI 90, PASI 100 and PGA responses were generally higher in patients without prior biologics. Week 8 PASI 50 response predicted PASI 90 response.
CONCLUSION
CONCLUSIONS
Pooled data confirmed the efficacy of tildrakizumab for moderate-to-severe plaque psoriasis.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Dermatologic Agents
0
Placebos
0
tildrakizumab
DEW6X41BEK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1098-1106Subventions
Organisme : Merck & Co., Inc.
Informations de copyright
© 2019 European Academy of Dermatology and Venereology.